The Future Of iPSCs With BlueRock Therapeutics' CEO Seth Ettenberg
Source: Cell & Gene
BlueRock Therapeutics' President and CEO Seth Ettenberg, Ph.D. talks to Cell & Gene: The Podcast listeners about the company's Phase 1 Clinical Trial for Advanced Parkinson’s Disease. Ettenberg also covers the most promising therapeutic applications for iPSCs currently in development as well as the major regulatory challenges that the field faces for their clinical use. We also cover how far iPSCs have come and what future progress may entail.
This website uses cookies to ensure you get the best experience on our website. Learn more